Key insights
- Anthropic, an AI chatbot developer, added Novartis CEO Vas Narasimhan to its board, signaling a potential IPO this year. This move, along with a prior board addition, strengthens Anthropic's governance as it expands into healthcare, partnering with pharmaceutical giants like Eli Lilly and Novo Nordisk. While not a direct market mover, it reflects growing AI adoption across sectors.
Investing.com -- Anthropic has appointed Vas Narasimhan, chief executive of Swiss pharmaceutical company Novartis, to its board of directors, the Wall Street Journal reported Tuesday.
The move marks the second board addition in recent months for the Claude chatbot developer, which added former Microsoft and General Motors executive Chris Liddell to its board in February.
The company is strengthening its board as it considers an initial public offering, potentially as soon as this year, and expands its enterprise push into healthcare.
The healthcare sector is a priority for Anthropic. The company has partnered with Eli Lilly, Novo Nordisk and Genmab with the aim of shortening drug development life cycles.
Anthropic co-founder Daniela Amodei said in a statement that Narasimhan had overseen the development and approval of more than 35 novel medicines in "one of the most regulated industries."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.